Sumitomo Dainippon | 4506

Sumitomo Dainippon traded at 864.00 this Monday February 6th, increasing 3.00 or 0.35 percent since the previous trading session. Looking back, over the last four weeks, Sumitomo Dainippon gained 4.95 percent. Over the last 12 months, its price fell by 30.43 percent. Looking ahead, we forecast Sumitomo Dainippon to be priced at 832.50 by the end of this quarter and at 752.54 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
864.00
Daily Change
0.35%
Yearly
-30.43%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
M3 Inc 3,686.00 -34.00 -0.91% -12.36%
Kyowa Hakko Kirin 2,883.00 1.00 0.03% -1.37%
Takeda 4,172.00 1.00 0.02% 21.17%
Astellas Pharma 1,903.00 13.50 0.71% -5.86%
Sumitomo Dainippon 864.00 3.00 0.35% -30.43%
Shionogi 6,263.00 56.00 0.90% -21.56%
Chugai Pharma 3,395.00 18.00 0.53% -16.36%
Eisai 7,679.00 -190.00 -2.41% 33.50%
Terumo 3,853.00 39.00 1.02% -7.04%
Daiichi Sankyo 4,057.00 -4.00 -0.10% 71.87%
Otsuka Holdings 4,115.00 28.00 0.69% 0.59%

Indexes Price Day Year
JP225 27700 190.30 0.69% 1.65%

Sumitomo Dainippon
Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other Overseas division is involved in the development of its products in Europe. The Company is also engaged in the manufacture, purchase, sale and supply of food materials and additives, chemical products, veterinary drugs, diagnostic products and inspection services of clinical pathology for animal, the manufacture of extracts, as well as the storage, delivery and clinical inspection of drugs.